Skip to main content

rapivab

Generic: peramivir injection

rapivab: developed by 1 company · 1 FDA decision.

rapivab evidence translation

What we can confirm

What it means

Source-backed records connect rapivab to BCRX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could rapivab → BCRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Acute Uncomplicated Influenza

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
BIOCRYST PHARMACEUTICALS INC (BCRX)
Acute Uncomplicated Influenza
Approved
FDA Decisions1 records
NDA206426Type 1 - New Molecular EntityStandardIntravenousSolution

Frequently asked questions

Who is developing rapivab?

rapivab is being developed by BIOCRYST PHARMACEUTICALS INC.

What is rapivab's latest FDA decision?

The most recent tracked FDA decision for rapivab is Approval, dated December 19, 2014.